$LQDA

Adair Jason sold $562K of LQDA

Adair Jason (Chief Business Officer) sold 7,863 shares of Liquidia Corp (LQDA) at an average of $71.51 ($71.39–$71.52, $0.56M total) across 2 trades on 2026-07-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Adair Jason
Published Jul 15, 2026, 12:05 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 15, 2026, 12:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$LQDA
Neutral
high confidence
Mentioned
$LQDA
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

The disclosure provides a concrete datapoint on insider selling activity (size, price range, and 10b5-1 status) but does not introduce new fundamentals like earnings, guidance, trial results, or regulatory actions.

02

Market read

Useful for monitoring insider behavior, but unlikely to drive a durable repricing without additional company-specific catalysts.

03

What to watch

Traders may over-weight insider selling; the key missing context is whether other insiders also sold/bought around the same window and whether the company has concurrent fundamental catalysts.

Relevance 4/10Novelty 3/10Timing: after-hours filing update on 2026-07-14 for a 2026-07-13 sale

Background

The article is a SEC Form 4 insider transaction disclosure for Liquidia Corp, reported by CBO Adair Jason.

Company-level read

Ticker impact

$LQDANeutralHigh confidence
Context

Liquidia Corp disclosed an insider open-market sale by CBO Adair Jason of 7,863 shares at about $71.51 on a 10b5-1 plan.

Expected impact

Likely limited near-term price impact; any reaction would be sentiment-driven rather than earnings or guidance-related.

Evidence & confidence

The filing is a Form 4 insider transaction with a pre-arranged 10b5-1 plan and no accompanying operational or financial disclosure.

Market effects

No clear sector read-through because the disclosure is an individual insider sale without new company guidance or clinical/regulatory updates.

None.

None.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may not reflect new negative information and could be mechanically scheduled.

Key entities

  • Liquidia Corp

    Company whose insider transaction was reported on Form 4.

  • Adair Jason

    Chief Business Officer who sold shares in an open-market transaction under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?

Liquidia Corporation (LQDA) is relying on Yutrepia, its inhaled dry-powder treprostinil therapy, to drive growth despite intense competition in the PAH market. Yutrepia generated $300.3M in sales in H1 2026 and has seen strong adoption. LQDA faces competition from United Therapeutics (UTHR) and Insmed (INSM), with UTHR expanding its PAH franchise. LQDA's shares have surged 96.3% YTD, trading at 6.16X forward sales. Analysts have lowered EPS estimates for 2026 and 2027.

$LQDAHighAI 8/10

Liquidia (LQDA) Q2 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q2 2026 earnings with YUTREPIA net sales at $170.4M, up 31% QoQ. Net income was $74.7M ($0.74/diluted share). The company guided 2027 revenue to exceed $1B. R&D expenses rose 185% YoY due to L606 program costs. Management highlighted strong patient adoption and market share growth.

$LQDAMedAI 8/10

LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth

Liquidia (LQDA) reported Q2 2026 EPS of 74 cents, above the Zacks estimate of 70 cents. Revenues rose to $171.7 million from $8.8 million a year earlier, beating the $165 million consensus, driven by Yutrepia net product sales of $170.4 million. Shares fell about 10% after results. Liquidia said it targets over $1 billion net revenues in 2027.

$LQDAMed

Liquidia Corp (LQDA): Results of Operations and Financial Condition

Liquidia Corp (LQDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Liquidia Corporation Reports Second Quarter 2026 Financial Results · YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $170.4 million in the second quarter of 2026, up 31% from the first quarter of 2026 · Approximately 5,900 unique patient